Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.
तुलना करने के लिए मीट्रिक्स | SHPH | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधSHPHपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.3x | −2.1x | −0.5x | |
PEG अनुपात | 0.00 | 0.09 | 0.00 | |
क़ीमत/बुक | 2.1x | 2.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 96.7x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 166.4% | 47.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 4.0% | 5.8% | अनलॉक करें |